Literature DB >> 19583965

Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates.

Gargi Ghosh1, Andrew G Lee, Sean P Palecek.   

Abstract

Epidermal growth factor receptor (EGFR) signaling plays an important role in a majority of solid tumors, and therapeutics targeted against EGFR has demonstrated promise in slowing growth of these tumors. However, many of these drugs either have failed to reproduce promising preclinical model results in clinical settings or have been successful in only a subgroup of cancer patients due partly to incomplete assessment of EGFR status in cancer. A patient-customized, predictive diagnostic for the effects of specific anti-EGFR therapies may improve outcomes. Here we report the development of a hydrogel-based protein array for quantitative and reproducible determination of the activity of EGFR directly from cellular extracts. In this study, we used glutathione S-transferase-fused Eps15 (GST-Eps15) fusion proteins immobilized within a polyacrylamide hydrogel as a substrate for quantifying EGFR kinase activity from the extracts of EGFR-expressing cell lines. Significant EGFR up-regulation was detected in a mixture containing 7% EGFR-overexpressing cell lysate diluted in lysate from a cell line expressing low levels of EGFR. In addition, the GST-Eps15 protein array was capable of detecting inhibition of EGFR activity when incubated with different tyrosine kinase inhibitors. These findings establish the potential of this protein-acrylamide copolymer hydrogel array not only to evaluate EGFR status in cancer cell lysates but also to screen for the most promising therapeutics for individual patients and monitor treatment progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19583965      PMCID: PMC2758617          DOI: 10.1016/j.ab.2009.07.002

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  32 in total

1.  Enzyme immunoassay of human epidermal growth factor receptor (hEGFR).

Authors:  R R Kumar; A Meenakshi; N Sivakumar
Journal:  Hum Antibodies       Date:  2001

2.  Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region.

Authors:  R Mandic; N Eikelkamp; R Peldszus; M Sadowski; A M Sesterhenn; A A Dünne; J A Werner
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

Review 3.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Authors:  Y Yarden
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 4.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 5.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.

Authors:  Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mori; Nagahiro Saijo; Kazuto Nishio
Journal:  Int J Cancer       Date:  2002-03-10       Impact factor: 7.396

Review 7.  Why the epidermal growth factor receptor? The rationale for cancer therapy.

Authors:  José Baselga
Journal:  Oncologist       Date:  2002

Review 8.  Epidermal growth factor receptor dependence in human tumors: more than just expression?

Authors:  Carlos L Arteaga
Journal:  Oncologist       Date:  2002

9.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

10.  Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis.

Authors:  S Confalonieri; A E Salcini; C Puri; C Tacchetti; P P Di Fiore
Journal:  J Cell Biol       Date:  2000-08-21       Impact factor: 10.539

View more
  8 in total

1.  Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.

Authors:  Gargi Ghosh; Xiaoliang Yan; Andrew G Lee; Stephen J Kron; Sean P Palecek
Journal:  Biosens Bioelectron       Date:  2010-08-03       Impact factor: 10.618

2.  Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels.

Authors:  Andrew G Lee; David J Beebe; Sean P Palecek
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

3.  Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.

Authors:  Alicia D Powers; Bi Liu; Andrew G Lee; Sean P Palecek
Journal:  Analyst       Date:  2012-07-20       Impact factor: 4.616

4.  Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.

Authors:  Alicia D Powers; Sean P Palecek
Journal:  J Healthc Eng       Date:  2012-12       Impact factor: 2.682

5.  Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate.

Authors:  Alicia D Powers; Wenquing Han; Bi Liu; Sean P Palecek
Journal:  Anal Bioanal Chem       Date:  2013-04-27       Impact factor: 4.142

6.  Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads.

Authors:  Gargi Ghosh; Xiaoliang Yan; Stephen J Kron; Sean P Palecek
Journal:  Assay Drug Dev Technol       Date:  2012-09-20       Impact factor: 1.738

7.  Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts.

Authors:  Michael R Mand; Ding Wu; Darren R Veach; Stephen J Kron
Journal:  J Biomol Screen       Date:  2010-03-17

8.  Development of macroporous poly(ethylene glycol) hydrogel arrays within microfluidic channels.

Authors:  Andrew G Lee; Christopher P Arena; David J Beebe; Sean P Palecek
Journal:  Biomacromolecules       Date:  2010-10-28       Impact factor: 6.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.